A traditional Chinese medicine composition, preparation and application for relieving cough.

Abstract

This invention relates to the field of traditional Chinese medicine (TCM) technology, specifically proposing a TCM composition, preparation, and its application. The raw materials of this TCM composition are composed of *Eclipta prostrata*, *Terminalia chebula*, mulberry leaves, *Ophiopogon japonicus*, and bitter almond. This TCM composition has the effects of resolving phlegm, astringing the lungs, relieving cough, and soothing the throat. It can be used in the preparation or research and development of antitussive drugs and has good application prospects.

Description

Technical Field

[0001] This invention relates to the field of traditional Chinese medicine technology, and in particular to a traditional Chinese medicine composition, preparation and its application. Background Technology

[0002] Post-infectious cough due to lung yin deficiency accounts for 48.4% of subacute cough cases. It refers to a persistent cough that persists even after respiratory infection symptoms have subsided, mainly manifested as a small amount of white, mucous sputum or an irritating dry cough. Colds, cold air, dust, and fumes can easily trigger or worsen the cough. In severe cases, intense coughing may be accompanied by shortness of breath, chest tightness, difficulty breathing, or atypical wheezing. The cough can last 3-8 weeks, or even longer. If the cough lasts longer than 8 weeks, the likelihood of cough-related complications increases more than twofold. Symptoms are easily recurred due to sudden weather changes or irritating odors, leading to repeated relapses and increasing patient suffering and financial burden. Therefore, early and effective intervention is crucial for preventing future risks, alleviating patient suffering, and improving their quality of life and health. This remains a critical issue that research urgently needs to address. Currently, Western medicine recommends bronchodilators, leukotriene preparations, and low-dose hormones to relieve bronchospasm and reduce inflammation, but these do not fundamentally improve chronic airway inflammation or lower the cough sensitivity threshold, impacting the patient's physical and mental health and social interactions.

[0003] A wide variety of pathogens can cause post-infectious cough due to lung yin deficiency, including influenza virus, rhinovirus, respiratory syncytial virus, mycoplasma, and chlamydia. The pathogenesis mainly involves airway inflammation and overstimulation. Pathogens cause widespread airway inflammation, prompting the release of large amounts of cytokines and inflammatory mediators such as IL-1, TNF-α, IL-6, IL-8, GRO-α, and eosinophil activation chemokine. This leads to excessive respiratory secretion and reflux stimulation of the pharynx, resulting in cough. This process is accomplished through the remodeling of airway epithelial cells and the induction of goblet cell metaplasia.

[0004] Traditional Chinese medicine has a long history, and based on the characteristics of the disease, most experts categorize it under "stubborn cough," "chronic cough," "wind cough," and "spasmodic cough." In terms of pathogenesis, it is mostly a case of excess pathogenic factors and deficiency of vital energy, with a mixture of both. Developing a traditional Chinese medicine composition that can address cough symptoms after infection due to yin deficiency is one of the urgent technical problems to be solved. Summary of the Invention

[0005] In view of this, the present invention proposes a traditional Chinese medicine composition with the effects of resolving phlegm, astringing the lungs, relieving cough and soothing the throat.

[0006] The present invention provides a traditional Chinese medicine composition with the effects of resolving phlegm, astringing the lungs, relieving cough, and soothing the throat. This composition consists of five distinctive Chinese medicinal herbs and is based on clinical practice, with bold innovations made on the foundation of classic ancient formulas. Simultaneously, it has been deeply developed according to the requirements of modern Chinese medicine technology to prepare a modern formulation. This maintains the quality of the original decoction while being convenient for patients to take, making it particularly suitable for large-scale industrial production.

[0007] The technical solution of the present invention is implemented as follows: The present invention provides a traditional Chinese medicine composition, which is composed of dwarf tea, Terminalia chebula, mulberry leaf, Ophiopogon japonicus and bitter almond.

[0008] In some embodiments, the traditional Chinese medicine composition consists of 12-18 parts of *Eriocaulon buergerianum*, 8-12 parts of *Terminalia chebula*, 5-7 parts of *Morus alba*, 8-11 parts of *Ophiopogon japonicus*, and 6-10 parts of *Prunus armeniaca*, calculated by weight.

[0009] In some embodiments, the traditional Chinese medicine composition consists of 15 parts of *Eriocaulon buergerianum*, 9 parts of *Terminalia chebula*, 5 parts of mulberry leaf, 8 parts of *Ophiopogon japonicus*, and 7 parts of bitter almond, calculated by weight.

[0010] The formula of the traditional Chinese medicine composition provided in the above embodiments is based on clinical practice of post-infectious cough due to lung yin deficiency and has been comprehensively innovated in combination with the basic theory of traditional Chinese medicine. The principal herb is *Ailanthus chinensis*, which has the effects of resolving phlegm and relieving cough, clearing damp heat, promoting blood circulation and removing blood stasis, and is suitable for both new and chronic coughs. *Terminalia chebula* (He Zi) astringes the lungs, relieves cough, reduces fire and soothes the throat, effectively astringes the lungs, lowers qi, reduces fire, relieves cough, soothes the throat, and opens the voice. *Ophiopogon japonicus* (Mai Dong) nourishes yin and generates fluids, moistens the lungs and clears the heart, and can treat dry cough due to lung dryness, consumptive cough due to yin deficiency, sore throat, thirst due to fluid depletion, and thirst due to internal heat; these are all used as assistant herbs. *Prunus armeniaca* (Ku Xing Ren) enhances the effects of lowering qi, relieving cough and asthma, moistens the intestines and promotes bowel movement. *Morus alba* (Sang Ye) disperses wind-heat, clears the lungs and moistens dryness; these are all used as adjuvant herbs. The combined use of these five herbs adds the effects of resolving phlegm, astringing the lungs, relieving cough and soothing the throat to the existing cough-relieving properties.

[0011] Secondly, the present invention also provides a pharmaceutically acceptable preparation made from the above-mentioned traditional Chinese medicine composition, the preparation type including decoction, pill, powder, ointment, elixir, medicated wine, tablet, injection, aerosol granules, etc.

[0012] In some embodiments, the present invention provides a granule prepared from the above-mentioned traditional Chinese medicine composition. The preparation method of the granule is as follows: after weighing the raw materials according to the weight ratio, water is added for extraction, volatile oil and extract are collected, the volatile oil is encapsulated with β-cyclodextrin to obtain volatile oil inclusion complex, the extract is filtered, and concentrated at 60-80℃ to an extract with a relative density of 1.05-1.2. After drying the extract, the volatile oil inclusion complex and excipients are added to prepare granules.

[0013] In the above embodiments, the mass ratio of volatile oil to β-cyclodextrin is 1:(4-8).

[0014] In some embodiments, the water extraction method in the above granule preparation method is as follows: first, add 10 times the amount of water, extract for 60 minutes, collect the volatile oil, then add 8 times the amount of water, extract for 30 minutes, and combine the two extracts.

[0015] In some embodiments, the present invention provides another granule prepared from the above composition. The preparation method of the granule is as follows: the raw materials are extracted with water, concentrated and dried to obtain five kinds of raw material granules, the five kinds of raw material granules are mixed according to the weight ratio of the raw materials and excipients are added to fill and prepare granules.

[0016] In some embodiments, the above-mentioned method for preparing granules by separately adding water includes the following steps: first adding 10 times the amount of water, extracting for 60 minutes, collecting the volatile oil, second adding 8 times the amount of water, extracting for 30 minutes, and combining the two extracts.

[0017] In some embodiments, the drying method in the above two granule preparation methods includes: spray drying the raw material to be dried, wherein the frequency of the induced draft fan for spray drying is 50 Hz, the frequency of the atomizer is 60 Hz, and the inlet air temperature is 160°C.

[0018] In some embodiments, the excipients include one or a combination of several of maltodextrin, dextrin, powdered sugar, povidone, polyethylene glycol, xylitol, and β-cyclodextrin.

[0019] In some implementations, the amount of excipients used is 2 to 5 times the amount of dry powder.

[0020] Thirdly, the present invention also provides a method for preparing a cough-relieving composition using the above-mentioned traditional Chinese medicine composition.

[0021] Fourthly, the present invention also provides a method for preparing a cough-suppressing composition using the above-mentioned formulation.

[0022] The present invention has the following advantages over the prior art:

[0023] The traditional Chinese medicine composition provided by this invention has the advantages of simplified formulation, small dosage, no controllable materials such as ephedra and poppy shell, and is safe and reliable. At the same time, it has good effect on reducing cytokines such as TNF-α, IL-1β and IL-6. Attached Figure Description

[0024] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0025] Figure 1 This is a bar chart comparing the cough onset time of different groups in the ammonia-induced cough method in mice according to embodiments of the present invention;

[0026] Figure 2 This is a bar chart comparing the number of coughs in different groups of mice induced by ammonia in an embodiment of the present invention.

[0027] Figure 3 This is a bar chart comparing the cough suppression rates of different groups in the ammonia-induced cough method in mice according to embodiments of the present invention;

[0028] Figure 4 This is a bar chart comparing the antitussive activity of different dosages in the experimental group of the mouse ammonia-induced cough method in this embodiment of the invention;

[0029] Figure 5 This is a comparative diagram showing the effects of ammonia-induced coughing on TNF-α cytokines in mouse serum samples during the mouse ammonia-induced coughing method in this embodiment of the invention.

[0030] Figure 6 This is a comparative diagram showing the effects of ammonia-induced coughing on IL-1β cytokines in mouse serum samples during the mouse ammonia-induced coughing method in this embodiment of the invention.

[0031] Figure 7 This is a comparative diagram showing the effects of ammonia-induced coughing on IL-6 cytokine in mouse serum samples during the mouse ammonia-induced coughing method in this embodiment of the invention.

[0032] Figure 8 This is a comparison chart of TCM symptom scores before and after treatment in an embodiment of the present invention. Detailed Implementation

[0033] The technical solutions of the present invention will be clearly and completely described below with reference to the embodiments of the present invention. Obviously, the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those of ordinary skill in the art without creative effort are within the scope of protection of the present invention.

[0034] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the embodiments of this invention pertain. If any definition stated in this section is contrary to or otherwise inconsistent with a definition stated in a patent, patent application, published patent application, or other publication incorporated herein by reference, the definitions listed here shall prevail over those incorporated herein by reference.

[0035] Unless otherwise specified, the methods used in the following embodiments are conventional methods. Unless otherwise specified, the materials, reagents, and instruments used are conventional materials, reagents, and instruments in the art, and can be obtained commercially by those skilled in the art.

[0036] When a quantity, concentration, or other value or parameter is expressed as a range, a preferred range, or a range defined by a series of upper and lower preferred values, this should be understood as specifically disclosing all ranges formed by any pair of any upper or preferred value with any lower or preferred value, regardless of whether the range is disclosed individually. For example, when the range “1 to 5” is disclosed, the described range should be interpreted as including ranges “1 to 4”, “1 to 3”, “1 to 2”, “1 to 2 and 4 to 5”, “1 to 3 and 5”, etc. When numerical ranges are described herein, unless otherwise stated, the range is intended to include its endpoints and all integers and fractions within that range. In this specification and claims, range definitions may be combined and / or interchanged, unless otherwise stated, these ranges include all subranges contained therein.

[0037] Example 1

[0038] This embodiment provides a traditional Chinese medicine granule form:

[0039] Traditional Chinese medicine granules are composed of the following raw materials in the indicated weight proportions:

[0040] 15 parts of dwarf tea, 9 parts of Terminalia chebula, 5 parts of mulberry leaves, 8 parts of Ophiopogon japonicus, and 7 parts of bitter almond.

[0041] Preparation method: Weigh 15 parts of *Tea globulus*, 9 parts of *Terminalia chebula*, 5 parts of mulberry leaf, 8 parts of *Ophiopogon japonicus*, and 7 parts of bitter almond, totaling 44 parts. First, add 440 parts of water, heat to boiling, and maintain the temperature for 60 minutes, collecting the volatile oil simultaneously. Filter to obtain the first extract. Second, add 352 parts of water, heat to boiling, and maintain the temperature for 30 minutes, filtering to obtain the second extract. Combine the two extracts and filter through a 120-mesh sieve. Concentrate at 70℃ until the relative density reaches 1.1 to obtain an extract. Spray dry the extract to obtain a dry powder. The spray drying parameters are: fan frequency 50Hz, atomizer frequency 60Hz, and inlet air temperature 160℃. Incorporate the volatile oil with 6 parts by weight of β-cyclodextrin to obtain a volatile oil inclusion complex. Mix the volatile oil inclusion complex with the dry powder and 1 part by weight of maltodextrin to form granules.

[0042] Example 2

[0043] This embodiment provides a traditional Chinese medicine granule form:

[0044] Traditional Chinese medicine granules are composed of the following raw materials in the indicated weight proportions:

[0045] 16 parts of dwarf tea, 10 parts of Terminalia chebula, 6 parts of mulberry leaves, 10 parts of Ophiopogon japonicus, and 8 parts of bitter almond.

[0046] Preparation method: Weigh 16 parts of *Tetrapanax papyriferus*, 10 parts of *Terminalia chebula*, 6 parts of mulberry leaf, 10 parts of *Ophiopogon japonicus*, and 8 parts of bitter almond, totaling 50 parts. First, add 500 parts of water, heat to boiling, and maintain the temperature for 60 minutes, collecting the volatile oil simultaneously. Filter to obtain the first extract. Second, add 400 parts of water, heat to boiling, and maintain the temperature for 30 minutes, filtering to obtain the second extract. Combine the two extracts, filter through a 120-mesh sieve, and concentrate at 70℃ until the relative density reaches 1.05 to obtain an extract. Spray dry the extract to obtain a dry powder. The spray drying parameters are: fan frequency 50Hz, atomizer frequency 60Hz, and inlet air temperature 160℃. Incorporate the volatile oil with 4 parts by weight of β-cyclodextrin to obtain a volatile oil inclusion complex. Mix the volatile oil inclusion complex with the dry powder and 1 part by weight of maltodextrin to form granules.

[0047] Example 3

[0048] This embodiment provides a traditional Chinese medicine granule form:

[0049] Traditional Chinese medicine granules are composed of the following raw materials in the indicated weight proportions:

[0050] 12 parts of dwarf tea, 8 parts of Terminalia chebula, 5 parts of mulberry leaves, 8 parts of Ophiopogon japonicus, and 6 parts of bitter almond.

[0051] Preparation method: Weigh 12 parts of *Tea globulus*, 8 parts of *Terminalia chebula*, 5 parts of mulberry leaf, 8 parts of *Ophiopogon japonicus*, and 6 parts of bitter almond, totaling 39 parts. First, add 390 parts of water, heat to boiling, and maintain the temperature for 60 minutes, collecting the volatile oil simultaneously. Filter to obtain the first extract. Second, add 312 parts of water, heat to boiling, and maintain the temperature for 30 minutes, filtering to obtain the second extract. Combine the two extracts and filter through a 120-mesh sieve. Concentrate at 70℃ until the relative density reaches 1.1 to obtain an extract. Spray dry the extract to obtain a dry powder. The spray drying parameters are: fan frequency 50Hz, atomizer frequency 60Hz, and inlet air temperature 160℃. Incorporate the volatile oil with 6 parts by weight of β-cyclodextrin to obtain a volatile oil inclusion complex. Mix the volatile oil inclusion complex with the dry powder and 2 parts by weight of maltodextrin to form granules.

[0052] Example 4

[0053] This embodiment provides a traditional Chinese medicine granule form:

[0054] Traditional Chinese medicine granules are composed of the following raw materials in the indicated weight proportions:

[0055] 18 parts of dwarf tea, 12 parts of Terminalia chebula, 7 parts of mulberry leaves, 11 parts of Ophiopogon japonicus, and 10 parts of bitter almond.

[0056] Preparation method: Weigh out 18 parts of *Tetrapanax papyriferus*, 12 parts of *Terminalia chebula*, 7 parts of mulberry leaf, 11 parts of *Ophiopogon japonicus*, and 10 parts of bitter almond, totaling 58 parts. First, add 580 parts of water, heat to boiling, and maintain the temperature for 60 minutes, collecting the volatile oil simultaneously. Filter to obtain the first extract. Second, add 464 parts of water, heat to boiling, and maintain the temperature for 30 minutes, filtering to obtain the second extract. Combine the two extracts, filter through a 120-mesh sieve, and concentrate at 70℃ until the relative density reaches 1.2 to obtain an extract. Spray dry the extract to obtain a dry powder. The spray drying parameters are: fan frequency 50Hz, atomizer frequency 60Hz, and inlet air temperature 160℃. Incorporate the volatile oil with 6 times its weight of β-cyclodextrin to obtain a volatile oil inclusion complex. Mix the volatile oil inclusion complex with the dry powder and 3 times its weight of maltodextrin to form granules.

[0057] Example 5

[0058] This embodiment provides a traditional Chinese medicine granule form:

[0059] Traditional Chinese medicine granules are composed of the following raw materials in the indicated weight proportions:

[0060] 15 parts of dwarf tea, 9 parts of Terminalia chebula, 5 parts of mulberry leaves, 8 parts of Ophiopogon japonicus, and 7 parts of bitter almond.

[0061] Preparation method: Weigh 15 parts of *Tea globulus*, 9 parts of *Terminalia chebula*, 5 parts of mulberry leaf, 8 parts of *Ophiopogon japonicus*, and 7 parts of bitter almond, totaling 44 parts. First, add 440 parts of water, heat to boiling, and maintain the temperature for 60 minutes, collecting the volatile oil simultaneously. Filter to obtain the first extract. Second, add 352 parts of water, heat to boiling, and maintain the temperature for 30 minutes, filtering to obtain the second extract. Combine the two extracts and filter through a 120-mesh sieve. Concentrate at 70℃ until the relative density reaches 1.1 to obtain an extract. Spray dry the extract to obtain a dry powder. The spray drying parameters are: fan frequency 50Hz, atomizer frequency 60Hz, and inlet air temperature 160℃. Incorporate the volatile oil with 8 times its weight of β-cyclodextrin to obtain a volatile oil inclusion complex. Mix the volatile oil inclusion complex with the dry powder and 4 times its weight of maltodextrin to form granules.

[0062] Example 6

[0063] This embodiment provides a traditional Chinese medicine granule form:

[0064] Traditional Chinese medicine granules are composed of the following raw materials in the indicated weight proportions:

[0065] 15 parts of dwarf tea granules, 9 parts of Terminalia chebula granules, 5 parts of mulberry leaf granules, 8 parts of Ophiopogon japonicus granules, and 7 parts of bitter almond granules.

[0066] Preparation method: First, add 150 parts of water to *Dwarf Tea*, heat to boiling, and keep warm for 60 minutes. Filter to obtain the first extract. Second, add 120 parts of water, heat to boiling, and keep warm for 30 minutes. Filter to obtain the second extract. Combine the two extracts and filter through a 120-mesh sieve. Spray dry the combined extract to obtain a dry powder. The spray drying parameters are: fan frequency 50Hz, atomizer frequency 60Hz, and inlet air temperature 160℃. *Dwarf Tea* granules are obtained. Other raw materials are prepared into corresponding granules using the same method. 15 parts of *Dwarf Tea* granules, 9 parts of *Terminalia chebula* granules, 5 parts of mulberry leaf granules, 8 parts of *Ophiopogon japonicus* granules, 7 parts of bitter almond granules, and 88 parts of maltodextrin are weighed, mixed, and granulated to obtain granules.

[0067] The granules prepared in the above examples were subjected to pharmacodynamic studies in mice.

[0068] SPF-grade healthy male Kunming mice were randomly divided into model groups, including a positive control group receiving pentoxyverine citrate tablets, and high, medium, and low dose groups, with 10 mice in each group. 0.5 h after gavage administration, the mouse cough-induced test was performed using the ammonia-induced cough method. The equivalent dosage was calculated based on the mouse's body surface area. The low, medium, and high dose groups of the granules prepared in Example 1 were administered at 1.85 g / kg, 2.73 g / kg, and 3.90 g / kg, respectively. The positive control group received pentoxyverine citrate 30 mg / kg via gavage, and the model groups received distilled water via gavage. The administration volume was 20 mL / kg. 0.2 mL of concentrated ammonia was injected into a cotton ball and placed in a 1 L inverted beaker. The mouse was then quickly placed in the beaker for 30 seconds before being removed. The mice's coughing behavior (open mouth, abdominal muscle contraction, sometimes accompanied by a coughing sound) was observed, and the cough latency (time from mouse placement to the onset of coughing) and the number of coughs within 3 minutes were recorded. Finally, blood was collected from each mouse, centrifuged, and serum was separated to measure the cytokines TNF-α, IL-1β, and IL-6.

[0069] Cough suppression rate (%) = (Average number of coughs in the model control group - Average number of coughs in the treatment group) / Average number of coughs in the model control group × 100%; Antitussive activity (%) = Cough suppression rate in the treatment group / Cough suppression rate in the positive control group × 100%.

[0070] Specific results are as follows Figures 1-4As shown, compared with the solvent control group, the medium and high doses of this product prolonged the cough onset time and reduced the number of coughs in mice, and both differences were significant (P<0.05 or P<0.01); the cough onset time, reduction in the number of coughs, cough suppression rate and antitussive activity of each dose group were all dose-dependent.

[0071] Further analysis of serum samples showed that ( ) Figures 5-7 After administration of this product, the levels of various cytokines in the serum of mice decreased to a certain extent, indicating that this product can inhibit the worsening of cough by reducing inflammatory factors, thereby exerting an antitussive effect.

[0072] Clinical efficacy research of traditional Chinese medicine:

[0073] Thirty patients diagnosed with cough due to lung yin deficiency through traditional Chinese medicine were collected. Each patient took the prescription or compound granules described in Example 1 of this invention under the guidance of a doctor for a period of 2 weeks. The traditional Chinese medicine symptoms before and after treatment were recorded according to the traditional Chinese medicine symptom scoring method in the table below. The average score of each symptom was calculated, and the differences before and after treatment were compared using statistical analysis methods.

[0074]

[0075]

[0076] The results are as follows Figure 8 As shown, according to Figure 8 Analysis shows that the TCM syndrome scores of each symptom decreased significantly after treatment, with statistically significant differences, indicating that this product has a good therapeutic effect on cough caused by lung yin deficiency.

[0077] The granules obtained in Examples 2-6 were subjected to pharmacodynamic studies in mice using the same method. The cough onset time, reduction in cough frequency, cough suppression rate, and antitussive activity of each dose group showed a dose-response relationship. The granules obtained in Examples 2-6 also showed good therapeutic effects on cough caused by lung yin deficiency in traditional Chinese medicine clinical efficacy studies.

[0078] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the protection scope of the present invention.

Claims

1. A traditional Chinese medicine composition for relieving cough, characterized in that, The raw materials of the traditional Chinese medicine composition, calculated by weight, consist of 12-18 parts of *Eriocaulon buergerianum*, 8-12 parts of *Terminalia chebula*, 5-7 parts of *Morus alba*, 8-11 parts of *Ophiopogon japonicus*, and 6-10 parts of *Prunus armeniaca*.

2. The traditional Chinese medicine composition for relieving cough as described in claim 1, characterized in that, The raw materials of the traditional Chinese medicine composition, calculated by weight, consist of 15 parts of *Eriocaulon buergerianum*, 9 parts of *Terminalia chebula*, 5 parts of mulberry leaf, 8 parts of *Ophiopogon japonicus*, and 7 parts of bitter almond.

3. A traditional Chinese medicine preparation for relieving cough, characterized in that, Made from the raw materials of the traditional Chinese medicine composition for relieving cough as described in claim 1 or 2.

4. The formulation according to claim 3, characterized in that, The formulation is a granule, and the preparation method of the granule is as follows: after weighing the raw materials according to the weight ratio, water is added for extraction, volatile oil and extract are collected, the volatile oil is encapsulated with β-cyclodextrin to obtain volatile oil inclusion complex, the extract is filtered and concentrated at 60-80℃ to an extract with a relative density of 1.05-1.2, the extract is dried and then the volatile oil inclusion complex and excipients are added to make granules.

5. The formulation as described in claim 4, characterized in that, The water extraction method includes: first adding 10 times the amount of water, extracting for 60 minutes, collecting the volatile oil, second adding 8 times the amount of water, extracting for 30 minutes, and combining the two extracts.

6. A traditional Chinese medicine preparation for relieving cough, characterized in that, The preparation is a granule. The preparation method of the granule is as follows: extract, concentrate and dry the dwarf tea, Terminalia chebula, mulberry leaf, Ophiopogon japonicus and bitter almond respectively with water to obtain five kinds of raw material granules. Mix the five kinds of raw material granules in the following proportions: 12-18 parts of dwarf tea granules, 8-12 parts of Terminalia chebula granules, 5-7 parts of mulberry leaf granules, 8-11 parts of Ophiopogon japonicus granules and 6-10 parts of bitter almond granules, and add excipients to fill and make granules.

7. The formulation according to claim 6, characterized in that, The water extraction method includes: first adding 10 times the amount of water, extracting for 60 minutes, collecting the volatile oil, then adding 8 times the amount of water, extracting for 30 minutes, and combining the two extracts.

8. The formulation as described in claim 4 or 7, characterized in that, The drying method includes spray drying the raw material, wherein the frequency of the induced draft fan for spray drying is 50 Hz, the frequency of the atomizer is 60 Hz, and the inlet air temperature is 160 ℃.

9. The formulation as described in claim 4 or 7, characterized in that, The excipients include one or a combination of several of the following: dextrin, powdered sugar, povidone, polyethylene glycol, and xylitol.

10. The formulation as described in claim 9, characterized in that, The dextrin includes one or a combination of two of maltodextrin and β-cyclodextrin.

Images